Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease

Valerie Anderson, Kim Burchiel, Penelope (Penny) Hogarth, Jacques Favre, John Hammerstad

Research output: Contribution to journalArticle

338 Citations (Scopus)

Abstract

Background: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited. Objective: To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD. Design: This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study. Setting: Oregon Health and Science University in Portland. Patients: Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS. Main Outcome Measures: Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up. Results: Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39% vs 48%). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38% in STN stimulation patients compared with 3% in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89% vs 62%). Cognitive and behavioral complications were observed only in combination with STN stimulation. Conclusion: Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease.

Original languageEnglish (US)
Pages (from-to)554-560
Number of pages7
JournalArchives of Neurology
Volume62
Issue number4
DOIs
StatePublished - Apr 2005

Fingerprint

Subthalamic Nucleus
Globus Pallidus
Deep Brain Stimulation
Parkinson Disease
Dyskinesias
Levodopa
Nucleus
Stimulation
Parkinson's Disease
Hypokinesia
Outcome Assessment (Health Care)
Medication

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. / Anderson, Valerie; Burchiel, Kim; Hogarth, Penelope (Penny); Favre, Jacques; Hammerstad, John.

In: Archives of Neurology, Vol. 62, No. 4, 04.2005, p. 554-560.

Research output: Contribution to journalArticle

@article{dd9f8142236e4aa4b2faea5d75c2a4ae,
title = "Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease",
abstract = "Background: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited. Objective: To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD. Design: This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study. Setting: Oregon Health and Science University in Portland. Patients: Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS. Main Outcome Measures: Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up. Results: Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39{\%} vs 48{\%}). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38{\%} in STN stimulation patients compared with 3{\%} in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89{\%} vs 62{\%}). Cognitive and behavioral complications were observed only in combination with STN stimulation. Conclusion: Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease.",
author = "Valerie Anderson and Kim Burchiel and Hogarth, {Penelope (Penny)} and Jacques Favre and John Hammerstad",
year = "2005",
month = "4",
doi = "10.1001/archneur.62.4.554",
language = "English (US)",
volume = "62",
pages = "554--560",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease

AU - Anderson, Valerie

AU - Burchiel, Kim

AU - Hogarth, Penelope (Penny)

AU - Favre, Jacques

AU - Hammerstad, John

PY - 2005/4

Y1 - 2005/4

N2 - Background: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited. Objective: To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD. Design: This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study. Setting: Oregon Health and Science University in Portland. Patients: Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS. Main Outcome Measures: Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up. Results: Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39% vs 48%). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38% in STN stimulation patients compared with 3% in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89% vs 62%). Cognitive and behavioral complications were observed only in combination with STN stimulation. Conclusion: Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease.

AB - Background: Deep brain stimulation (DBS) of the globus pallidus interna (GPi) and subthalamic nucleus (STN) has been reported to relieve motor symptoms and levodopa-induced dyskinesia in patients with advanced Parkinson disease (PD). Although it has been suggested that stimulation of the STN may be superior to stimulation of the GPi, comparative trials are limited. Objective: To extend our randomized, blinded pilot comparison of the safety and efficacy of STN and GPi stimulation in patients with advanced PD. Design: This study represents the combined results from our previously published, randomized, blinded, parallel-group pilot study and additional patients enrolled in our single-center extension study. Setting: Oregon Health and Science University in Portland. Patients: Twenty-three patients with idiopathic PD, levodopa-induced dyskinesia, and response fluctuations were randomized to implantation of bilateral GPi or STN stimulators. Patients and evaluating clinicians were blinded to stimulation site. All patients were tested preoperatively while taking and not taking medications and after 3, 6, and 12 months of DBS. Main Outcome Measures: Postoperatively, response of symptoms to DBS, medication, and combined medication and DBS was evaluated. Twenty patients (10 in the GPi group and 10 in the STN group) completed 12-month follow-up. Results: Off-medication Unified Parkinson's Disease Rating Scale motor scores were improved after 12 months of both GPi and STN stimulation (39% vs 48%). Bradykinesia tended to improve more with STN than GPi stimulation. No improvement in on-medication function was observed in either group. Levodopa dose was reduced by 38% in STN stimulation patients compared with 3% in GPi stimulation patients (P = .08). Dyskinesia was reduced by stimulation at both GPi and STN (89% vs 62%). Cognitive and behavioral complications were observed only in combination with STN stimulation. Conclusion: Stimulation of either the GPi or STN improves many features of advanced PD. It is premature to exclude GPi as an appropriate target for DBS in patients with advanced disease.

UR - http://www.scopus.com/inward/record.url?scp=16844371374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844371374&partnerID=8YFLogxK

U2 - 10.1001/archneur.62.4.554

DO - 10.1001/archneur.62.4.554

M3 - Article

C2 - 15824252

AN - SCOPUS:16844371374

VL - 62

SP - 554

EP - 560

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 4

ER -